Cover Image

A comparative study of efficacy of lamotrigine and levetiracetam in the continuous maintenance phase of patients with bipolar depressive disorder

Daryani K. K.*, Narendra Kumar Bokade, O. P. Raichandani


Bipolar disorder, or manic-depressive illness (MDI), is one of the most common, severe, and persistent mental illnesses. Bipolar disorder is a serious lifelong struggle and challenge The objective of this study is to evaluate the spectrum of efficacy of Lamotrigine versus Levetiracetam as add on therapy comparatively in patient with bipolar depressive disorder who are inadequately responsive to or intolerant of pharmacotherapy with conventional drugs at Jabalpur and adjoining area. In this 60 days open label, randomized comparative study 60 patients were enrolled, out of which 53 patients were evaluated at the end of the study. Two parallel groups were differentiated by the study medication-Lamotrigine or Levetiracetam-that was administered as an adjunct to existing medications for bipolar depressive disorder (N=60). At baseline and every 15th days Mood symptoms were rated using the Hamilton depression scale. Total 61% patients in Lamotrigine group had shown marked improvement on HAM-D (>50% reduction on day 60) while 33% patients in Levetiracetam group showed this level of improvement. On comparison between these two drugs on the basis of HAM-D the difference was statistically significant (P value for HAM-D < 0.05). The addition of either Lamotrigine or levetiracetam to patients preexisting mood stabilizing regimen was associated with a reduction in the frequency of mood fluctuation. Evidence from this preliminary open-label study suggests that Lamotrigine was more efficacious than Levetiracetam in reducing depressive symptoms in patients presenting with depressive phases of bipolar I and bipolar II disorder.


Bipolar disorder; Lamotrigin; Levetiracetam

Full Text:



American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, DSM-IV-TR. Washington, DC: 2000.

Summary of bipolar disorder available at

Benazzi F, Hecker Psychiatry Research Center, a University of California at San Diego (USA) Collaborating Center at Forli, Italy. Bipolar II disorder: epidemiology, diagnosis and management. / [PubMed - indexed for MEDLINE]/2010 Jun 23;2. pii: 47

Bowden C, Singh V. Long-term Management of Bipolar Disorder. Available at Accessed Dec 31, 2003.

Ng F, Hallam K, Lucas N, Berk M/The role of Lamotrigine in the management of bipolar disorder. Journal of clinical psychiatry 2007 Aug; 3 (4):463-74.

Peter braunig, Klinik für Psychiatrie; Verhaltensmedizin und Psychosomatik, Chemnitz, University of Dresden, Dresden, Germany. Stephanie Kruger. Levetiracetam in the Treatment of Rapid Cycling Bipolar Disorder. J Psychopharmacol. 2003 Jun; 17 (2):239-41.

Hamilton M, A rating scale for depression. J NeurolNeurosurg Psychiatry 1960; 23: 56–62.

Peter BräunigKlinikfür, Psychiatrie; Verhaltensmedizin und Psychosomatik, Chemnitz, University of Dresden, Dresden, Germany.Stephanie KrügerLevetiracetam in the Treatment of Rapid Cycling Bipolar Disorder.

Calabrese JR, Bowden CL. Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of Lamotriginemonotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60:79-88.

Barbosa L, Berk M, Vorster M, A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003; 64:403-407.

Stephanie Krüger & Rahul Sarkar & Ramona Pietsch & Levetiracetam as monotherapy or add-on to Valproate in the treatment of acute mania-a randomized Psychopharmacology (2008) 198:297–299; DOI 10.1007/ s002 13-008/ 1109-8.



  • There are currently no refbacks.

Copyright (c) 2014 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.